Enclomiphene to Improve Testosterone - Quick Reference Sheet

Enclomiphene to Improve Testosterone

Created on 07/03/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

An oral medication that raises a man's own testosterone by releasing a brake in the brain, keeping the testes active so sperm production is generally preserved — unlike testosterone gels or injections. The evidence that it raises testosterone is strong and consistent, but whether men actually feel better is less firmly established, and long-term safety data are limited. (Full Review)

Protocol

Starting Dose
12.5 mg once daily
Following the doses used in the Phase III trial program
Titration
Up to 25 mg daily
If the testosterone response is insufficient after several weeks
Timing
Morning dosing
To align with the natural morning peak of testosterone
Time to effect
Testosterone & LH
1–2 weeks
Testosterone and luteinizing hormone begin rising
Full Normalization
4–16 weeks
Fuller normalization of testosterone levels
Symptom Improvement
Several weeks later
Typically lags the biochemical changes

Benefits

Contraindications
  • Primary (testicular) hypogonadism
  • History of venous thromboembolism, active clotting disorders, or recent clot (DVT or PE within prior 3–6 months)
  • Untreated significant retinal or optic-nerve disease
  • Hormone-sensitive concerns (e.g., active or suspected prostate cancer)
  • Significant liver impairment
  • Women
Key Interactions
  • Aromatase inhibitors (anastrozole, letrozole, exemestane)
  • Human chorionic gonadotropin (hCG) and gonadotropins
  • Exogenous testosterone (gels, injections, pellets)
  • Anticoagulants and antiplatelet agents (warfarin, apixaban, aspirin)
  • CYP-interacting drugs (rifampin, carbamazepine, St. John's wort, ketoconazole, ritonavir, clarithromycin)
  • Over-the-counter and supplement interactions

Risk & Side Effects

  • High: Elevated estradiol
  • Medium: Mood changes and irritability; reduced libido or energy; visual disturbances
  • Low: Venous thromboembolism; elevated hematocrit
  • Speculative: Long-term unknowns from off-label compounded use

Monitoring

Marker Target Why
Total testosterone 500–800 ng/dL Primary efficacy marker
Free testosterone 100–200 pg/mL Reflects usable, unbound hormone
Luteinizing hormone (LH) Rising above baseline; mid-normal or above Confirms the axis is being stimulated
Follicle-stimulating hormone (FSH) Rising above baseline Supports sperm production
Estradiol (E2) 20–40 pg/mL Detects excess estrogen from the testosterone rise
Hematocrit 40–50% Detects blood thickening
Sex hormone-binding globulin (SHBG) 20–45 nmol/L Interprets total vs. free testosterone
Prostate-specific antigen (PSA) < 1.5 ng/mL (age-dependent) Prostate safety before raising testosterone
Semen analysis (sperm concentration) > 15 million/mL Confirms fertility preservation

Cadence: First recheck at about 4–6 weeks, again at 3 months, then every 6–12 months once stable

Qualitative Assessment

  • Energy levels and daytime fatigue
  • Libido and sexual function
  • Mood, motivation, and sense of well-being
  • Cognitive clarity and concentration
  • Exercise performance and recovery
  • Preserved testicular size (a practical sign the axis remains active)